Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000732898 | SCV000860896 | uncertain significance | not provided | 2018-04-27 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001307389 | SCV001496801 | uncertain significance | UDPglucose-4-epimerase deficiency | 2020-04-21 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C0"). This variant has not been reported in the literature in individuals with GALE-related conditions. ClinVar contains an entry for this variant (Variation ID: 596921). This variant is present in population databases (rs150326189, ExAC 0.01%). This sequence change replaces aspartic acid with histidine at codon 327 of the GALE protein (p.Asp327His). The aspartic acid residue is moderately conserved and there is a moderate physicochemical difference between aspartic acid and histidine. |